Paeds Cases · endocrinology-diabetes-and-growth
Type 1 diabetes: diagnosis and initial management — structured clinical encounter
Structured encounter testing the diagnosis and first management of a six-year-old with a two-week history of thirst, polyuria and weight loss who is alert and not acidotic with a glucose of 22 mmol/L: confirming the diagnosis on glucose, excluding ketoacidosis at the bedside, naming the type with autoantibodies and C-peptide, starting subcutaneous basal-bolus insulin, delivering structured family education, and explaining the honeymoon phase and the rule that insulin is never stopped.
On this page & tools
Target exams
Clinical context
This is a textbook presentation of new-onset type 1 diabetes at stage 3, the clinical onset, in a child who is alert and not acidotic. The task is to confirm the diagnosis quickly, exclude ketoacidosis so the correct pathway is chosen, start subcutaneous insulin, and begin the family education that lets the diabetes be managed at home. The type-defining tests are sent but do not delay treatment. [1]
Candidate tasks
- Confirm the diagnosis and state the glucose or HbA1c criteria that establish diabetes in this child. [2]
- Perform the bedside assessment that decides the treatment pathway, and state what makes this child suitable for the uncomplicated route. [1]
- Start the initial insulin regimen and state the approximate dose and how it is split. [3]
- Deliver structured education to the family, covering the core skills before discharge. [3]
- Explain the honeymoon phase the family will encounter and the single rule they must never break. [4]
Key discussion points
- Diagnosis: Diabetes is confirmed on glucose — a random level of 11.1 mmol/L or higher with symptoms (met here at 22 mmol/L), a fasting level of 7.0 or higher, or an HbA1c of 48 mmol/mol (6.5 percent) or higher. A single high reading in a symptomatic child is sufficient. Islet autoantibodies and C-peptide are sent to confirm type 1 but must not delay insulin. [2]
- Bedside triage: Measure capillary or blood ketones with venous pH and bicarbonate, and assess hydration, conscious level and breathing. This alert, well-perfused, non-acidotic child tolerating fluids with only mildly raised ketones is suitable for the subcutaneous pathway; a child with acidosis or significant ketosis would go to the DKA protocol. [1]
- Initial insulin: Start a subcutaneous basal-bolus regimen at about 0.5 to 1.0 units per kilogram per day, split roughly half basal (long-acting analogue once or twice daily) and half bolus (rapid analogue with meals), titrated to the glucose pattern over the first weeks. [3]
- Education: Blood glucose monitoring, carbohydrate counting and meal-time dosing, recognition and treatment of hypoglycaemia with fast carbohydrate, sick-day rules built on never stopping insulin, injection technique and site rotation, and clear contact instructions, delivered by the diabetes nurse educator and dietitian. [3]
- Honeymoon: Over the coming weeks the insulin requirement will fall as surviving beta cells recover. This is the honeymoon (partial remission), it is temporary, and insulin is never stopped, however small the dose, because stopping it leads back to ketoacidosis. [4]
Communication objectives
Explain to a frightened family that the diagnosis is serious but manageable and that they will be taught everything they need. Use plain language, check understanding, and provide written information with a named team contact and follow-up. Set the expectation of the honeymoon at the outset so that a later fall in insulin need is understood as expected and does not tempt the family to stop insulin. [3]
References
- [1]DiMeglio LA; Evans-Molina C; Oram RA Type 1 diabetes. Lancet, 2018.PMID 29916386
- [2]de Bock M; Agwu JC; et al International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Glycemic Targets. Horm Res Paediatr, 2024.PMID 39701064
- [3]Cengiz E; Danne T; et al International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Insulin and Adjunctive Treatments in Children and Adolescents with Diabetes. Horm Res Paediatr, 2024.PMID 39884261
- [4]Couper JJ; Haller MJ; et al ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents. Pediatr Diabetes, 2018.PMID 30051639